Does rosmarinic acid underestimate as an experimental cardiovascular drug?1

Seria o ácido rosmarínico subestimado como droga cardiovascular experimental?

Luciana Garros Ferreira1, Andrea Carla Celotto1, Verena Kise Capellini11, Agnes Afrodiite Sumarelli Albuquerque11, Tales Rubens de Nadai1, Marco Tulio Menezes de Carvalho11, Paulo Roberto Barbosa Evora11

1Fellow Master degree, Postgraduate Program in Medical Surgical Clinic from the Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo (FMRP-USP). Ribeirão Preto – SP, Brazil. Acquisition and interpretation of data, collection of study information, manuscript writing.
IIIPhD, Postgraduate Program in Medical Surgical Clinic from the Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo (FMRP-USP). Ribeirão Preto – SP, Brazil. Acquisition and interpretation of data, collection of study information.
IIIIPhD, Postgraduate Program in Medical Surgical Clinic from the Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo (FMRP-USP). Ribeirão Preto – SP, Brazil. Acquisition and interpretation of data, collection of study information.
IVFellow Master degree, Postgraduate Program in Medical Surgical Clinic from the Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo (FMRP-USP). Ribeirão Preto – SP, Brazil. Acquisition and interpretation of data, collection of study information, manuscript writing.
VMD, Postgraduate Program in Medical Surgical Clinic from the Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo (FMRP-USP). Ribeirão Preto – SP, Brazil. Acquisition and interpretation of data, collection of study information.
VIFellow Master degree, Postgraduate Program in Medical Surgical Clinic from the Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo (FMRP-USP). Ribeirão Preto – SP, Brazil. Acquisition, collection of study information.
VIIFull Professor, Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo (FMRP-USP). Ribeirão Preto – SP, Brazil. Intellectual and scientific content of the study, supervised all phases, manuscript writing.

ABSTRACT

PURPOSE: The rationale of the present review is to analize the activity of Rosmarinus officinalis in the the cardiovascular system

METHODS: A MEDLINE database search (from January 1970 to December 2011) using only rosmarinic acid as searched term.

RESULTS: The references search revealed 509 references about rosmarinic acid in 40 years (the first reference is from 1970). There is a powerful prevalence of antioxidant and cancer studies. Other diseases are few cited, as inflammation, brain (Alzheimer and Parkinson disease) and, memory; allergy; diabetes; atherosclerosis, and; hypertension. It is necessary to consider the complete absence of studies on coronary artery disease, myocardial ischemia, heart failure or ischemia/reperfusion injury.

CONCLUSION: Rosmarinic acid is underestimated as an experimental cardiovascular drug and deserves more attention.

Key words: Rosmarinus officinalis. Polyphenols. Cardiovascular diseases.

RESUMO

OBJETIVO: A justificativa da revisão é analisar a atividade de Rosmarinus officinalis no sistema cardiovascular

MÉTODOS: Uma busca de banco de dados MEDLINE (de janeiro de 1970 a dezembro de 2011), utilizando apenas o ácido rosmarínico como termo pesquisado.

RESULTADOS: A busca referências revelou 509 referências sobre o ácido rosmarínico em 40 anos (a primeira referência é de 1970). Há uma prevalência poderosa antioxidante e estudos do câncer. Outras doenças são few cited, como inflamação, braço (doença de Alzheimer e Parkinson) e, memória, hipertensão, alergia, diabetes, aterosclerose, e. É necessário ter em conta a ausência completa de estudos sobre a doença de artérias coronárias, isquemia do miocárdio, insuficiência cardíaca ou isquemia / lesão de reperfusão.

CONCLUSÃO: O ácido rosmarínico é subestimado como uma droga experimental cardiovascular e merece mais atenção.

Introduction

*Rosmarinus officinalis* is popularly known in Brazil as rosemary. The presence of rosmarinic acid (RA) in medicinal plants, herbs and spices, has been generated healthy and beneficial effects. Among these were several RA biological activities, including antioxidant, astringent, anti-inflammatory, antimicrobial, antiangiogenic, antiviral, antirheumatic, antiallergic, antidepressant, antidiabetic, and antitumor. However, reports on its activity in the cardiovascular system are scarce.

Methods

A MEDLINE database search (from January 1970 to December 2011) using only rosmarinic acid as searched term.

Results

A MEDLINE database search (until December 2011) shows 509 references about rosmarinic acid in 40 years (the first reference is from 1970) (Figure 1). The interest for the phytoterapeutic increased in the last decade. There is a powerful prevalence of antioxidant (374 references) and cancer (33 references) studies. Other subjects are limited: inflammation (23 references); brain (Alzheimer disease, Parkinson disease, memory) (18 references); allergy (8 references); diabetes (11 references); atherosclerosis (5 references), hypertension (4 references) and sepsis (2 references). It is necessary to view the complete absence of studies on coronary artery disease, myocardial ischemia, heart failure or ischemia/reperfusion injury (Figure 2). This is the rationale of the present review.

Discussion

**Rosmarinic acid pharmacological properties**

Extract of rosemary relaxes smooth muscles of the trachea and intestine and has choleretic, hepatoprotective and antitumorogenic activity. RA, $C_{18}H_{16}O_8$, is the most prominent constituents of rosemary (Figure 3). Structurally, the RA is an ester of caffeic acid and lactic acid 3,4 dihidroxifenil. These acids are widely distributed in the vegetable kingdom. Biogenetic studies from Mentha species (mint) showed that two aromatic amino acids, phenylalanine and tyrosine are incorporated into the RA. Part of caffeic acid, interestingly, is formed by part of the phenylalanine and 3,4 dihidroxifenil lactic acid is formed by tyrosine. These compounds have an antioxidant effect. RA is easily absorbed from the gastrointestinal tract and skin. It increases the production of prostaglandin E2, reduces the production of leukotriene B4 in human polymorphonuclear leukocytes, and inhibits the complement system. It is concluded that rosemary and its constituents, especially caffeic acid derivatives such as rosmarinic acid, have a therapeutic potential in treatment or prevention of bronchial asthma, spasmogenic disorders, peptic ulcer, inflammatory diseases, hepatotoxicity, atherosclerosis, ischaemic heart disease, cataract, cancer and reduced sperm motility.
Rosmarinic acid and cardiovascular diseases

1. Cardiomyopathy

The study used melatonin to induce rat cardiopathology. The administration of luteolin and echinochrome provided to 100% animal probability of survival. At the same time, mitochondrial apparatus of cardiomyocytes was characterized by the normal parameter, therefore, given preparations have provided of a protective effect at cardiomyocytes level. However, similar activities for rosmarinic acid have not shown16.

Other study was undertaken to investigate the inhibitory effect of RA on adriamycin (ADR)-induced apoptosis in H9c2 cardiac muscle cells at a mechanistic level. In vitro, ADR significantly decreased the viabilities of H9c2 cells, and this was accompanied by apoptotic features, such as a change in nuclear morphology and caspase protease activation. RA was found to inhibit these apoptotic characteristics by reducing intracellular reactive oxygen species (ROS) generation and by recovering the mitochondrial membrane potential. Results of this exhaustive study suggested that RA can inhibit ADR-induced apoptosis, proposing that RA should be viewed as a potential chemotherapeutic that inhibits cardiototoxicity in ADR-exposed patients17.

Inside this same research program, the cardioprotective effect of Prunella vulgaris ethylacetate fraction (PVEF) and its constituent RA was evaluated on isolated rat cardiomyocytes subjected to doxorubicin-induced oxidative stress. The cytotoxicities effect of PVEF and RA were concentration-dependent in the range of 0.005 to 0.05 mg/ml and the effect of PVEF correlated with the RA content. As found, the mechanism of the cardioprotective effects of the extract is most probably linked with the antioxidant capacity due to its high content of phenolic acids, mainly RA. It’s associated with scavenging of free radicals formed during application of doxorubicin and inhibition of lipid peroxidation of membrane systems as mitochondria, which positively influences the energy capacity of cardiomyocytes. Dexrazoxan, used as a positive control, was less effective than PVEF or RA18. In addition, chemoprotective effect of plant phenolics (caffeic, chlorogenic and rosmarinic acids) against anthracycline-induced toxicity on rat cardiomyocytes were reported19.

2. Rosmarinic acid, dislipidemia and atherosclerosis

Exogenous molecules from dietary sources such as polyphenols are highly effective in preventing the alteration of lipid membranes by oxidative stress. Among the polyphenols, the RA is an important compound studied. One full investigation attested the effectiveness of RA in preventing lipid peroxidation and in interacting with lipids. The study of transferred lipid/RA monolayers by atomic force microscopy revealed that 1 mol% of RA, in the membrane, was not sufficient to alter the membrane structure at the nanoscale. By fluorescence, the investigators observed no significant modification of membrane permeability and fluidity caused by the interaction with RA. They prepared 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC)/RA vesicles that evidenced, for the first time that up to 1 mol% of RA inserts spontaneously in the membrane, which is strong enough to prevent lipid peroxidation without any noticeable alteration of the membrane structure due to RA insertion13.

There are suggestive evidences that oxidatively modified low-density lipoprotein (LDL) is atherogenic, and that atherosclerosis can be attenuated by natural antioxidants, which inhibit LDL oxidation. Natural antioxidants combinations exist in nature aimed one study to determine the in vitro and in vivo effects of tomato lycopene, alone or in combination with other natural antioxidants, on LDL oxidation. The polyphenols glabridin (derived from licorice), rosmarinic acid or carnosic acid (derived from rosemary), as well as garlic (which contains a blend of natural antioxidants) inhibited LDL oxidation in a dose-dependent manner. When lycopene was added to LDL in association with these polyphenols, synergistic antioxidative effects were obtained against LDL oxidation induced either by copper ions or the radical generator 2',2'-Azobis 2-amidino propane hydrochloride (AAPH). After administering a fatty meal containing lycopene in the form of tomato oleoresin, postprandial LDL isolated 5 hour after meal consumption exhibited a significant reduced susceptibility to oxidation by 21%. The study concluded that lycopene acts synergistically, as an effective antioxidant against LDL oxidation, with some natural antioxidants such as vitamin E, the flavonoid glabridin, the phenolics rosmarinic acid and carnosic acid, and garlic. These observations suggest a greater antiatherogenic property to a combination of different natural antioxidants over that of an individual one3.

3. Rosmarinic acid and metabolic syndrome

One study investigated whether RA supplementation prevents cardiac abnormalities and hypertension in fructose-fed rats (FFR), as the RA has insulin-sensitizing and antioxidant effects in high fructose-fed model of insulin resistance. RA supplementation to FFR significantly improved insulin sensitivity,
reduced lipid levels, oxidative damage, and the expression of p22phox subunit of nicotinamide adenine dinucleotide phosphate reduced oxidase, and prevented cardiac hypertrophy. The blood pressure was also lowered by RA through a decrease in endothelin-1 and angiotensin-converting enzyme activity and increase in nitric oxide levels. Histology revealed a decrease in myocardial damage, in RA-supplemented FFR. From these findings, it is suggested that RA acts as a vasoactive substance and a cardioprotector through its antioxidant effects. Thus, RA may be useful in reducing the cardiovascular risk associated with IR.

4. Rosmarinic acid and hypertension

Although there are currently large selections of antihypertensive agents available for the treatment of hypertension, cardiovascular problems related to this disease continue to affect millions of people worldwide. Currently, the use of medicinal plants as a therapeutic option in various diseases, among them cardiovascular diseases, has gained ground. This is due to several factors, including the high cost of manufactured drugs, although the government is providing some anti-hypertensive, lack of public access to healthcare and pharmaceutical industries, the opportunity to make compounds with pharmacological activities often superior to current medications and a tendency for consumers to use natural products. Thus, the discovery of new substances with anti-hypertensive medication, low cost and rare adverse effects is still an attractive and beneficial aspect for clinical use. However, difficulties are encountered for this purpose including the possibility of an experimental model, obtaining standardized extracts and the difficulty of obtaining, isolation and identification of active substances.

High-blood pressure (HBP) is a common cardiovascular disease that affects millions of people worldwide. There are several ways to treat hypertension, such as the use of inhibitors of angiotensin-converting enzyme (ACE). In recent years, it has been demonstrated in vitro the inhibitory effect of some plant species on ACE and RA is a prominent constituent of these species. However, literature reports about its activity in the cardiovascular system are scarce.

The RA effect on BP could be related to inhibition and/or modulation of ACE, as shown by Li et al. and Karthik et al. (2011), or the endothelium-dependent vasodilator effect of RA as reported by Ersoy et al. (2008). The mechanisms involved in this relaxing effect remain unknown. Nevertheless, this effect was attributed to the fact that RA is a polyphenolic compound and, according to recent studies, these compounds would have vasodilator activity, through activation of NO pathway, endothelium-dependent hyperpolarizing factor (EDHF) and prostacyclin (PGI2). In addition, other possible mechanisms may be involved in this response, as in endothelial cells, which increased levels of Ca++ and activation of the PI3-kinase/Akt lead to a rapid and sustained activation of the enzyme nitric oxide synthase (NOS) and hyperpolarization. A third suggested mechanism is the RA antioxidant effect. The RA presents itself as a potent inhibitor of •O2 and an effective protector of tissue damage caused by peroxynitrite.

Conclusions

As RA is, nowadays, investigated in our laboratory, we carried out the presented MEDLINE search, and, it was a surprise the number of references about cardiovascular diseases. So we planned to share our uncertainty illustrated on the text title: does rosmarinic acid underestimte as a cardiovascular current drug? We trust that it is because we are getting satisfactory results on rat models of hypertension. In an overview, we hypothesize that AR deserves more experimental and clinical research in the cardiovascular milieu.

References

Does rosmarinic acid underestimate as an experimental cardiovascular drug?

Does rosmarinic acid underestimate as an experimental cardiovascular drug?


Acknowledgements

This study was partially supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FAEPA/HCFMRP/USP), SP, Brazil.

Correspondence:
Paulo Roberto B. Evora
Rua Rui Barbosa, 367/15, 14015-120 Ribeirão Preto – SP Brasil
Tel./Fax: (55 16)3602-2497
prbevora@fmrp.usp.br

Conflict of interest: none
Financial sources: FAPESP, FAEPA, CNPq

1Research performed at Laboratory of Endothelial Function, Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo, Brazil.